Viral Safety for Biologicals

Screen and Detect New Adventitious Agents, Optimise Viral Clearance and Implement Upstream and Downstream Viral Risk.

24-25 Jun 2014 at Pullman Cologne, Cologne, Germany

Medical & Health Care, Pharmaceuticals/Drug Discovery

Viral Safety for Biologicals 24-25 Jun 2014 Pullman Cologne, Cologne, Germany
Submit new post
Thank you for posting.
Share it:

Speakers ({{speakersCount}})

Show all

18+ industry case studies on minimising viral contamination risk including new insights from Eli Lilly and Company, Merck Serono, Regeneron Pharmaceuticals and Novartis Pharma AG.
Independent analysis from Baxter BioScience on the application and implementation of next-generation detection technologies for rapid virus identification.
Genzyme and Sanofi Pasteur evaluate the implementation of upstream viral clearance barriers to reduce the risk of contamination from raw materials and media.
Roche Diagnostics present the first FDA approved viral clearance design space following QbD principles.
NEW interactive strategic panel discussions on dealing with pressure release during nanofiltration and strategies to handle suspected contaminations.
Critical regulatory advice from the FDA and PEI on the use of next-generation detection technologies, in-house data in viral clearance and viral safety standards expected.

From: June 24, 2014 08:30
To: June 25, 2014 17:00

Pullman Cologne, 14 Helenenstraße, 50667, Cologne, Germany


Medical & Health Care, Pharmaceuticals/Drug Discovery

Contact email

Contact phone
+49 020 3377 3148

External link

Submitted by:

evvnt Platform

Are you the organizer?

Get in touch